Plus Therapeutics Adds Diagnostics Veteran Ron Andrews to Board
Event summary
- Plus Therapeutics appointed Ron Andrews, a diagnostics industry veteran with 35 years of experience, to its Board of Directors on March 26, 2026.
- Andrews has led organizations like Abbott Diagnostics, Roche Molecular Diagnostics, and Thermo Fisher, and has been instrumental in over $600M of capitalization and $15B in exits.
- Andrews will support the scaling of CNSide, a diagnostic tool for identifying leptomeningeal metastases, first in the U.S. and then globally.
- CNSide Diagnostics, LLC, a subsidiary of Plus Therapeutics, develops and commercializes the CNSide® CSF Assay Platform for managing leptomeningeal metastases.
The big picture
The appointment of Ron Andrews reflects Plus Therapeutics' push to scale its CNSide diagnostic tool, leveraging Andrews' extensive industry network and experience. This move aligns with broader trends in precision diagnostics and the growing focus on managing central nervous system cancers. Andrews' track record in capitalizing and exiting diagnostic companies suggests a strategic emphasis on maximizing CNSide's market potential and driving shareholder value.
What we're watching
- Strategic Scaling
- How Ron Andrews' global diagnostics industry connections will accelerate the commercialization of CNSide beyond the U.S.
- Diagnostic Innovation
- Whether CNSide can become a standard tool in managing leptomeningeal metastases, given its unique cerebrospinal fluid analysis.
- Execution Risk
- The pace at which Plus Therapeutics can integrate Andrews' expertise to drive value for stockholders and improve patient outcomes.
Related topics